Clinical Trial Update: Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial assessing safety and activity of enhanced TCR-transduced autologous T cells in metastatic melanoma was terminated; results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Enhanced TCR Transduced Autologous T Cells (TCR-transduced autologous T cells)

Snippet

Sponsor: Adaptimmune | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-05-08